Research-driven, since 2018.

Founded by two eminent researchers with one conviction: quality generics are a must, not an option.

About us

130+ studies, filed with the USFDA and EMA.

BioRadius Therapeutic Research is a research-driven company, founded in 2018 by two eminent researchers on the principle that quality generics are a must, not an option. Since its inception, BioRadius has completed more than 130 studies and filed them with international regulatory agencies including the USFDA and EMA.

We support pharmaceutical, biotech and medical device companies with clinical trials, bioequivalence studies, bioanalytical services, monitoring and product characterization, helping with cost containment, revenue growth and faster market reach. We align our services to help clients navigate regulatory pathways efficiently and shorten the clinical trial lifecycle, without compromising on quality.

  • Build confidence through bioequivalence and clinical trials
  • Take your drug to the market, quicker
  • Tailor economical solutions to each client

It's in our DNA

Four bases, one excellence.

Founded to deliver excellence in bioequivalence, BioRadius's DNA is made of these four bases.

A: Adherence to timelines

Efficient project management to deliver projects within the stipulated time.

T: Tested quality

Inspected and audited by third-party and sponsor QA teams. Inspected by the USFDA with zero observations: zero 483s.

G: Governed by regulatory guidelines

Every project is carried out following all applicable guidelines.

C: Cost effectiveness

Reach out to see how competitive we are, in both quality and cost.

Only the best

We tick all three boxes.

Quality

No compromise on quality. Pilot or pivotal, our eye for quality stays the same on every project.

Timeline

We understand how much timelines matter; sometimes they make all the difference. We don't sign a project unless we foresee finishing it within the stipulated timeline.

Cost effectiveness

We serve small and medium-sized international and national pharma companies with custom-tailored, cost-effective solutions that move products to market.

100+ Man-years of experience
130+ Completed projects
24 Field workers
18 Office staff

Our vision

What you feel, you can heal.

In classical geometry, a radius is a line segment that starts at the centre and reaches out to the edge of the circle. In the same way, BioRadius was founded to sit at the centre of pharma research while extending its reach to any point in the healthcare industry.

Our vision is to be a substantial stakeholder in the pharmaceutical industry, bringing drugs and devices to patients of every economic stratum efficiently, cost-effectively and on time.

Towards this vision, BioRadius Therapeutic Research provides custom-tailored, cost-effective bioequivalence research to generic pharmaceutical companies, to promote quality, affordable medicines.

Leadership

The people behind the science

Research professionals with high-level experience at esteemed international organizations.

Dr. Senthil ThyagarajanFounder Director & Head CRO

Dr. Senthil Thyagarajan is the Founder Director and Head CRO of BioRadius Therapeutic Research. A renowned researcher in stem cell and clinical research, he previously served as Director & Head CRO of BioClin Research, a bioequivalence CRO, and of NCORD Biotech, a regenerative medicine facility conducting clinical research on regenerative cell-based products. He is also Director, Scientific & Operations, and a partner at Novo Cellular Medicine Institute, Trinidad & Tobago.

He brings more than 13 years of high-level scientific research and management experience, gained in premier pharma and research institutes across several countries. At NCORD Biotech, he set up a clean-room facility for stem cell production and led clinical trial planning and conduct and business development. At BioClin Research, as founder director, he established a DCGI-approved bioequivalence CRO and ran operations and business development as Head CRO.

Before his work in India, he was a postdoctoral scientist at Abbott Pharmaceuticals in Ludwigshafen, Germany, and at the Max Planck Institute of Neurobiology in Munich, focusing on clinical research, novel stem cell assays for drug screening, and cell biology. At Abbott, he was part of StemBANCC, a five-year research programme funded by the Innovative Medicines Initiative (IMI) with academic and industry partners across 11 countries, and contributed to a drug discovery platform based on human iPSC-derived neural stem cells.

He holds a PhD in Neurobiology from the Max Planck Institute for Brain Research in Frankfurt, Germany. His work has been published in leading international peer-reviewed journals and presented at national and international conferences. Beyond research and management, he is motivated by the challenge of improving business models for science-driven ventures.

  • PhD, Max Planck Institute
  • Abbott Pharmaceuticals
  • StemBANCC (IMI)
  • 13+ years
  • Stem cell & clinical research

Have a product in the pipeline?

Let's bring it to the market together. Tell us about your product and timelines, and we'll come back with a plan and a quote.